Condition

Systemic Lupus Erythematosus (SLE) clinical trials and research

• 50Clinical trials
• 5NIH research projects
• 38Countries

Newest Systemic Lupus Erythematosus (SLE) clinical trials

All recruiting trials (50)

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• Triple therapy with voclosporin, MMF and prednisolone in lupus nephritis

  This trial tests whether adding voclosporin to standard lupus nephritis treatment (MMF and prednisolone) early on improves kidney inflammation compared to standard therapy alone.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07760480

• Carotid ultrasound to guide prevention of heart disease in inflammatory rheumatic diseases

  In people with inflammatory rheumatic diseases like RA, PsA, AxSpA, or SLE who are at modest cardiovascular risk, a carotid ultrasound test is used to see if they should start stronger lipid-lowering therapy to prevent heart problems.

  Recruiting at 7 sites Phase 4 Instituto de Investigación Marqués de Valdecilla · Alicante, Alicante and 16 other locations · NCT07611747

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Anti-CD19/BCMA CAR‑NK cell therapy for refractory pediatric rheumatic diseases

  This trial will test a single injection of engineered CAR‑NK cells aimed at CD19 and BCMA to see if it is safe and helps children aged 5 and older whose rheumatic diseases have not responded to other treatments.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07490041

• SG301 subcutaneous injection for people with active lupus

  This study will test whether SG301, given as an under-the-skin injection, can help people with active, autoantibody-positive systemic lupus erythematosus who have not adequately responded to standard treatments.

  Recruiting at 39 sites Phase 2 Hangzhou Sumgen Biotech Co., Ltd. · Beijing, Beijing Municipality and 39 other locations · NCT07447986

• Dual-target universal CAR-T cell therapy for refractory lupus

  This trial will test an off-the-shelf dual-target CAR-T cell therapy (QT-019B) to see if it is safe and tolerable in adults with refractory systemic lupus erythematosus.

  Recruiting at 3 sites Phase 1 Hangzhou Qihan Biotech Co., Ltd. · Hefei, Anhui and 2 other locations · NCT07444307

• Early heart muscle changes to spot severe pediatric lupus

  This project will test whether non-invasive heart ultrasound measurements can help identify children with severe, treatment-resistant lupus.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07425730

• TI-0032-III injection for relapsed and refractory B cell–related autoimmune diseases

  This trial tests whether TI-0032-III, an injected therapy that delivers circular RNA instructions for a CD19 CAR to T cells, can help adults with relapsed or treatment‑resistant B cell–related autoimmune diseases such as SLE, Sjögren's, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 Therorna · Shanghai, Shanghai Municipality · NCT07413341

• Comparing two biologic induction regimens and standard mycophenolate therapy for active proliferative lupus nephritis over six months

  This trial will test whether biologic induction therapy with belimumab or telitacicept leads to better kidney responses over six months than standard mycophenolate-based treatment in people aged 14–65 with active proliferative lupus nephritis.

  Recruiting Phase 2 Nanjing University School of Medicine · Nanjing, Jiangsu · NCT07340463

• Universal CD19/CD20 CAR-T cell injection for moderate to severe refractory systemic lupus erythematosus

  This study will try a universal CD19/CD20 CAR‑T cell infusion (CT1195E) to see if it is safe and helps adults 18–65 with moderate to severe refractory SLE.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07339332

• Enpatoran for adults with skin lupus, with or without systemic disease

  This 24-week test will see if enpatoran tablets reduce active skin lesions in adults with cutaneous lupus, with or without systemic lupus.

  Recruiting at 74 sites Phase 3 EMD Serono · Los Angeles, California and 73 other locations · NCT07332481

• LUCAR-G79D for adults with relapsed or refractory lupus or inflammatory muscle disease

  This trial will test an experimental CAR‑T cell treatment called LUCAR‑G79D in adults whose lupus or inflammatory muscle disease has returned or not responded to other treatments.

  Recruiting at 2 sites Phase 1 Nanjing Legend Biotech Co. · Bengbu, Anhui and 4 other locations · NCT07331272

• A CAR-T therapy for hard-to-treat systemic lupus with or without lupus nephritis

  This phase 2a study tests a single infusion of ICG318 CAR-T cells in adults and eligible teens with refractory SLE, with or without lupus nephritis.

  Recruiting Phase 2 iCell Gene Therapeutics · Chicago, Illinois and 3 other locations · NCT07328581

• YTS109 cell therapy for relapsed or treatment‑resistant autoimmune diseases

  This will try a single infusion of YTS109 immune cells in adults 18–65 with relapsed or treatment‑resistant autoimmune diseases such as lupus, Sjogren’s, systemic sclerosis, inflammatory myopathies, or ANCA‑associated vasculitis.

  Recruiting at 2 sites Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Xuzhou, Jiangsu and 1 other locations · NCT07236801

• Cizutamig treatment for people with systemic lupus erythematosus

  This study tests whether cizutamig is safe and shows early clinical benefit for adults with active SLE.

  Recruiting at 17 sites Phase 1 Candid Therapeutics · Beijing, Beijing Municipality and 16 other locations · NCT07215663

• 626 added to standard treatment for systemic lupus (SLE)

  This trial will test whether adding the drug 626 to standard care reduces disease activity and is safe for adults with systemic lupus (SLE).

  Recruiting Phase 1/2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Beijing, Beijing Municipality · NCT07185269

• Treatment outcomes for people with active SLE not helped by steroids and multiple immunosuppressants

  It will see how well current treatments work and how safe they are for people with active SLE who haven't had enough benefit from glucocorticoids and at least two immunosuppressant drugs.

  Recruiting at 53 sites Bristol-Myers Squibb · La Jolla, California and 69 other locations · NCT07175285

• YTS109 cell therapy for relapsed/refractory autoimmune diseases

  This trial will try a single infusion of YTS109 immune cells to see if they are safe and help adults aged 18–65 with relapsed or refractory autoimmune diseases such as lupus, Sjogren’s syndrome, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Tianjin · NCT07123519

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This trial will try a single infusion of YTS109 cells to see if they are safe and help adults (18–65) with relapsing or refractory autoimmune diseases such as SLE, lupus nephritis, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Hefei, Anhui · NCT07104721

• Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases

  This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.

  Recruiting at 2 sites Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo and 1 other locations · NCT07087912

• HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases

  This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.

  Recruiting Phase 1 Hadassah Medical Organization · Jerusalem · NCT07085676

• Umbilical-cord stem cell treatment for adult lupus

  This trial will test whether infusions of donated umbilical-cord mesenchymal stem cells can help adults aged 18–65 with moderate to severe systemic lupus erythematosus.

  Recruiting Phase 1/2 Shenzhen Beike Bio-Technology Co., Ltd. · Shenzhen, Guangdong · NCT07041801

• ct1192 CD19/CD20 CAR‑T cell therapy for moderate to severe refractory SLE

  This study will try one infusion of ct1192 universal CD19/20 CAR‑T cells in adults with moderate to severe lupus that has not responded to standard treatments.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07031713

• YK012 for moderate-to-severe lupus (SLE)

  This study will test YK012 in adults with moderate-to-severe lupus to see if it is safe and can lower disease activity.

  Recruiting Phase 1/2 Excyte Biopharma Ltd · Beijing, Beijing Municipality · NCT07010835

• Evaluating OL-108 for autoimmune diseases that have not responded to previous treatments

  This study is testing a new treatment called OL-108 to see if it can help people with autoimmune diseases that haven't improved with other therapies.

  Recruiting at 2 sites Phase 1 Beijing GoBroad Hospital · Beijing and 1 other locations · NCT06980597

• YTS109 cell therapy for relapsed or refractory systemic autoimmune diseases

  This trial will try a single infusion of YTS109 cells to see if it's safe and helps adults 18–65 with relapsed or refractory systemic autoimmune diseases such as SLE, systemic sclerosis, inflammatory myopathies, ANCA-associated vasculitis, or antiphospholipid syndrome.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Beijing, Beijing Municipality · NCT06978647

• Universal anti-CD70 CAR-T (CHT101) treatment for relapsed, treatment-resistant systemic lupus (SLE)

  This trial will try a universal anti-CD70 CAR-T cell therapy (CHT101) in adults with relapsed or treatment-resistant systemic lupus (SLE).

  Recruiting Early Phase 1 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT06946485

• Lupus patient registry for better understanding and care

  This study is collecting information from adults with lupus to help improve understanding and care for the disease.

  Recruiting Lupus Foundation of America · Washington D.C., District of Columbia · NCT06927219

• CAR T-cell therapy for patients with relapsed or refractory lupus

  This study is testing a new CAR T-cell therapy to see if it can help people with lupus who haven't found relief from other treatments.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06902844

• CD19-targeted CAR-T (MC-1-50) for adults with refractory SLE

  This trial will try a rapid-manufactured CD19-directed CAR-T cell therapy called MC-1-50 in adults whose SLE has not responded to standard treatments.

  Recruiting at 2 sites Phase 1 Chongqing Precision Biotech Co., Ltd · Hefei, Anhui and 1 other locations · NCT06892145

• Safety evaluation of CC312 in patients with autoimmune diseases

  This study is testing a new treatment called CC312 to see if it's safe and tolerable for adults with autoimmune diseases like lupus and rheumatoid arthritis.

  Recruiting Early Phase 1 CytoCares Inc · Tianjin, China · NCT06888960

• Continued deucravacitinib treatment for people with systemic or cutaneous lupus who completed earlier trials

  This open-label extension lets people with systemic lupus or discoid/subacute cutaneous lupus who finished specific earlier trials continue taking deucravacitinib to see if ongoing treatment remains safe and tolerable.

  Recruiting at 2 sites Phase 4 Bristol-Myers Squibb · Farmington, Connecticut and 3 other locations · NCT06875960

• CART19 treatment for lupus in young patients

  This study is testing a new treatment called CART19 to see if it can help young people aged 12-29 with tough-to-treat lupus feel better and improve their health.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839976

• CT1190B treatment for severe lupus and scleroderma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can help adults with severe lupus or scleroderma who haven't responded to other treatments.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06822881

• Using blinatumomab to treat difficult cases of childhood lupus

  This study is testing if a medication called blinatumomab can help children with tough cases of lupus feel better and manage their symptoms.

  Recruiting at 2 sites Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT06789107

• Cell therapy using UC-MSCs for patients with lupus

  This study is testing if a new treatment using stem cells from umbilical cords can help adults with lupus feel better and improve their kidney health.

  Recruiting Phase 1 LiveKidney.Bio · Charleston, South Carolina · NCT06737380

• JY231 injection for treating active systemic lupus erythematosus

  This study is testing a new injection called JY231 to see if it can safely help people with active lupus who have already tried other treatments.

  Recruiting Phase 1/2 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Kunming, Yunnan · NCT06675422

• Evaluating DR-0201 for autoimmune diseases

  This study is testing a new drug called DR-0201 to see if it can help people with autoimmune diseases like lupus and Sjogren's syndrome feel better and how safe it is.

  Recruiting at 8 sites Phase 1 Sanofi · Melbourne, Victoria and 7 other locations · NCT06647069

• Using CD19 CAR T cells to treat refractory systemic lupus erythematosus

  This study is testing if a new type of immune cell therapy can help people with hard-to-treat systemic lupus erythematosus feel better.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06585514

• Evaluating lupus outcomes after using Anifrolumab in real-world settings

  This study is testing how well Anifrolumab works for people with lupus when added to their usual treatment, focusing on improvements in their symptoms over a year.

  Recruiting at 5 sites AstraZeneca · Buenos Aires and 31 other locations · NCT06314282

• Evaluating FT819 for autoimmune diseases

  This study is testing a new treatment called FT819 to see if it can safely help people with moderate to severe autoimmune diseases feel better.

  Recruiting at 21 sites Phase 1 Fate Therapeutics · Beverly Hills, California and 20 other locations · NCT06308978

• C-CAR168 treatment for autoimmune diseases not responding to standard therapy

  This study is testing a new treatment called C-CAR168 to see if it can help adults with autoimmune diseases that haven't improved with standard therapies.

  Recruiting Phase 1 RenJi Hospital · Shanghai, Shanghai Municipality · NCT06249438

• Evaluating the effects of NAD+ boosting on immunity in lupus patients

  This study is testing if taking a supplement called nicotinamide riboside can help improve the immune system and reduce inflammation in women with lupus.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06032923

• Using CAR NK cells to treat systemic lupus erythematosus

  This study is testing a new type of immune cell treatment to see if it can safely help people with moderate to severe lupus who haven't responded well to other treatments.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT06010472

• Registry and biorepository for lupus patients

  This study is gathering information and samples from over 3,500 people with lupus to help researchers learn more about the condition and improve treatments.

  Recruiting at 22 sites Lupus Research Alliance · Birmingham, Alabama and 24 other locations · NCT05934149

• Evaluating the effectiveness of GnRHa for ovarian protection in women with lupus undergoing cyclophosphamide treatment

  This study is testing whether a hormone treatment can help protect the ovaries of women under 40 with lupus who are getting chemotherapy.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05567198

• Comparing treatments for lupus nephritis without added oral steroids

  This study is testing whether a treatment for lupus nephritis using obinutuzumab and mycophenolate mofetil without steroids can work just as well as a treatment that includes steroids.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Paris · NCT04702256

NIH-funded research (5)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Antiviral factors that limit HIV in people with SLE

  Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.

  NIH research Howard University · Washington, United States · NIH-11470887

• Mechanistic clues about lupus from immune disorders

  This grant looks at why certain immune disorders in people with genetic immune problems lead to lupus-like symptoms, by studying patients and mouse models.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11449228

• Immune-based blood tests to guide lupus care

  A patient-friendly blood test approach is being developed to spot early lupus flares and guide treatment before damage happens.

  NIH research Progentec Diagnostics, INC. · Oklahoma City, UNITED STATES · NIH-11325429

• Improving blood tests to better manage lupus disease activity

  This study is working on new blood tests to help people with lupus better understand their disease and catch flare-ups earlier, so they can get treatment sooner and avoid serious health issues.

  NIH research Progentec Diagnostics, INC. · Oklahoma City, UNITED STATES · NIH-11124845

• Investigating if Epstein-Barr Virus causes Systemic Lupus Erythematosus

  This study is looking at whether the Epstein-Barr virus might be linked to Systemic Lupus Erythematosus by comparing blood samples from military personnel who develop lupus with those who don’t, to see if there are any differences that could help us understand how lupus might start.

  NIH research Cincinnati VA Medical Center Research · Cincinnati, United States · NIH-10951532

Related topics

Quick answers

How many Systemic Lupus Erythematosus (SLE) clinical trials are recruiting right now?

50, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 38 countries. The most sites are in China (31 trials), United States (13 trials), France (4 trials), United Kingdom (3 trials), Brazil (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 19, Phase 1/2: 8, Early Phase 1: 5, Phase 4: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →